BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34815134)

  • 1. Linear late gadolinium enhancement in the basal anterior septum and lateral wall may represent the contrast enhancement of vessels: A CMR and CCTA comparison study.
    Ma P; Shang Y; Hu Y; Liu J; Zhou X; Wang J
    J Cardiol; 2022 May; 79(5):581-587. PubMed ID: 34815134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is the mid-wall linear high intensity "lesion" on cardiovascular magnetic resonance late gadolinium enhancement?
    Nakamura M; Kido T; Hirai K; Tabo K; Tanabe Y; Kawaguchi N; Kurata A; Kido T; Yamaguchi O; Mochizuki T
    J Cardiovasc Magn Reson; 2020 Sep; 22(1):66. PubMed ID: 32921308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Doesch C; Sperb A; Sudarski S; Lossnitzer D; Rudic B; Tülümen E; Heggemann F; Schimpf R; Schoenberg SO; Borggrefe M; Papavassiliu T
    Arch Cardiovasc Dis; 2015; 108(6-7):356-66. PubMed ID: 25863428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of Replacement Fibrosis in Hypertrophic Cardiomyopathy.
    Liu J; Zhao S; Yu S; Wu G; Wang D; Liu L; Song J; Zhu Y; Kang L; Wang J; Song L
    Radiology; 2022 Feb; 302(2):298-306. PubMed ID: 34726536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.
    Nakamura T; Iwanaga Y; Yasuda M; Kawamura T; Miyaji Y; Morooka H; Miyazaki S
    Int J Cardiovasc Imaging; 2016 Apr; 32(4):613-20. PubMed ID: 26589516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ventricular late potentials and myocardial fibrosis in hypertrophic cardiomyopathy.
    Matsuki A; Kawasaki T; Kawamata H; Sakai C; Harimoto K; Kamitani T; Yamano M; Matoba S
    J Electrocardiol; 2020; 58():87-91. PubMed ID: 31790854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young.
    Österberg AW; Östman-Smith I; Jablonowski R; Carlsson M; Green H; Gunnarsson C; Liuba P; Fernlund E
    Pediatr Cardiol; 2021 Mar; 42(3):492-500. PubMed ID: 33515326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial Fibrosis in Hypertrophic Cardiomyopathy: Volumetric Assessment of Late Enhancement Provided by Cardiac Computed Tomography.
    Langer C; Schaefer P; Lutz M; Eden M; Hohnhorst M; Harders H; Faber L; Jansen O; Both M; Frey N
    J Comput Assist Tomogr; 2015; 39(5):797-803. PubMed ID: 26125299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial perfusion reserve quantified by cardiac magnetic resonance imaging is associated with late gadolinium enhancement in hypertrophic cardiomyopathy.
    Tezuka D; Kosuge H; Terashima M; Koyama N; Kishida T; Tada Y; Suzuki JI; Sasano T; Ashikaga T; Hirao K; Isobe M
    Heart Vessels; 2018 May; 33(5):513-520. PubMed ID: 29168014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A radiomic approach to predict myocardial fibrosis on coronary CT angiography in hypertrophic cardiomyopathy.
    Qin L; Chen C; Gu S; Zhou M; Xu Z; Ge Y; Yan F; Yang W
    Int J Cardiol; 2021 Aug; 337():113-118. PubMed ID: 33961944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Cardiac Magnetic Resonance Study.
    Habib M; Adler A; Fardfini K; Hoss S; Hanneman K; Rowin EJ; Maron MS; Maron BJ; Rakowski H; Chan RH
    JACC Cardiovasc Imaging; 2021 May; 14(5):947-958. PubMed ID: 33248971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.
    Almaas VM; Haugaa KH; Strøm EH; Scott H; Smith HJ; Dahl CP; Geiran OR; Endresen K; Aakhus S; Amlie JP; Edvardsen T
    Heart; 2014 Apr; 100(8):631-8. PubMed ID: 24368281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced myocardial septal function assessed by cardiac magnetic resonance feature tracking in patients with hypertrophic obstructive cardiomyopathy: associated with histological myocardial fibrosis and ventricular arrhythmias.
    Song Y; Bi X; Chen L; Yang K; Chen X; Dong Z; Wang J; Kong X; Zhao K; Wang H; Duru F; Lu M; Ma L; Qiao S; Zhao S
    Eur Heart J Cardiovasc Imaging; 2022 Jul; 23(8):1006-1015. PubMed ID: 35167663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Yuki H; Utsunomiya D; Shiraishi S; Takashio S; Sakamoto F; Tsuda N; Oda S; Kidoh M; Nakaura T; Tsujita K; Yamashita Y
    Heart Vessels; 2018 Jun; 33(6):623-629. PubMed ID: 29230571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.